Tumor microenvironment plays a key role in tumorigenesis, progression and clinical response through intercellular interactions. Single cell genome analysis enables us to understand the cellular network in tumor and also clinical response to immunotherapy. Based on large single cell transcriptome data annotated with clinical information, we can discover novel cellular and molecular target for drug development
1. Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY. Accurate Prediction of Immunotherapy Response in Real-world Clinical Samples of Low Tumor Purity by Tumor Mutation Burden Measured by Panel Sequencing. Journal for Immunotherapy of Cancer. 2020 Oct8(2):e001199.
2. Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH, Joo KM, Park WY. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Medicine 2020 May 2712(1):47.
3. Yun JW, Yang L, Park HY, Lee CW, Cha H, Shin HT, Noh KW, Choi YL, Park WY*, Park PJ*. Dysregulation of cancer genes by recurrent intergenic fusions. Genome Biology 2020 Jul 621(1):166. *co-corresponding authors
4. Lee HO, Hong Y, Etlioglu HE, Cho YB, Pomella V, Bosch BV, Vanhecke J, Verbandt S, Hong H, Min JW, Kim N, Eum HH, Qian J, Boeckx B, Lambrechts D, Tsantoulis P, Hertogh G, Chung W, Lee T, An M, Shin HT, Joung JG, Jung MH, Ko G, Wirapati P, Kim SH, Kim HC, Yun SH, Tan IBH, Ranjan B, Lee
5. WY, Kim TY, Choi JK, Kim YJ, Prabhakar S, Tejpar S, Park WY. Genetic triggers and microenvironmental signal amplification determine the immune landscape of colorectal cancer. Nature Genetics 2020 Jun52(6):594-603.
6. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY*, Lee SH*. Corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in non-small cell lung cancer patients. Annals of Oncology 2020 Apr 19:S0923-7534(20)39295-4. *co-corresponding authors
(Tel) +82-2-3410-6128,
(Email) woongyang@g.skku.edu